2. From the opening performance, the three major indexes collectively opened lower, and then began to fluctuate higher. These characteristics of the disk are the most obvious:Today's A-share shrinkage is too obvious. Don't expect to get out of the anti-package, and it is not allowed to do so now. Institutions will definitely exert their strength when the market is calm. Today is the slow cow that meets the above requirements, but when the mood is calm, the quantity will also come down. How to understand it?Because yesterday, when the mood was the highest, it was inevitable that the turnover would be enlarged. Today, everyone has calmed down, and the volume will drop. Everyone's willingness to trade is not so strong. Some major institutions have done more by themselves. Typically, they don't want everyone to make money.
Everyone still tries to choose the direction of holding shares and wait patiently for the policy to be fulfilled.For retail investors, today is still more suitable for holding shares to rise. If you bought yesterday, you don't have to worry about it in the short term. As long as you follow the above-mentioned directions of technology, consumption and real estate, at least the policy is supportive, and it is not chasing high in the short term.At this time, institutions will either choose some high dividends or some oversold industry leaders as a defense. Those who want to catch the daily limit and buy and sell in day trading are more likely to lose money.
If you choose the right direction, the rest is the problem of holding shares. If you don't find the right direction, you will increase your workload.Now it is the hope of the above that the stock market will rise, and that technology and consumption will rise. This is not difficult to understand. What is difficult is whether you have the patience and confidence to hold these.The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.
Strategy guide
12-14
Strategy guide 12-14
Strategy guide 12-14